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Abstract
Pumilio/fem-3 mRNA binding factor (FBF) proteins are characterized by a sequence-specific
RNA-binding domain. This unique single-stranded RNA recognition module, whose sequence
specificity can be reprogrammed, has been fused with functional modules to engineer protein
factors with various functions. Here we summarize the advancement in developing RNA
regulatory tools and opportunities for the future.
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Introduction
Isaac Newton based his first Rule of Reasoning in Philosophy on the teleological principle
of purposeful design and assertion that “Nature is pleased with simplicity.” Such simplicity
is often illustrated in Nature’s elegant solution to control gene expression with a modular
molecule. In many key gene expression steps, such as DNA transcription or RNA splicing,
the regulatory proteins usually comprise a nucleic acid binding module to recognize target
and a functional module to activate or inhibit the biochemical process. This simple design
principle has also been adopted by humans to engineer protein factors to manipulate DNA/
RNA. For specific recognition of RNA, Nature evolved an RNA-binding module, the PUF
(Pumilio/FBF) scaffold, whose specificity, itself simple and modular, is determined by
combination of functional base recognition repeats. This unique RNA-binding mode allows
one to reprogram the specificity of the PUF scaffold with a small number of mutations, thus
generating novel engineered protein factors to modulate RNA metabolism. In this review,
we present the design principles, current progress, and future outlook of engineering protein
factors with a PUF domain as the RNA-binding scaffold. A broader review of many
different RNA-binding modules and their utility for engineering specificity accompanies our
more focused report [1].
Drosophila melanogaster Pumilio and Caenorhabiditis elegans FBF are the founding
members of the PUF family of RNA regulatory proteins. Pumilio is encoded by a maternal
gene required for abdominal development in Drosophila [2]. FBF was selected by yeast 3-
hybrid as a protein that binds to an RNA sequence in the 3′ untranslated region (UTR) of
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fem-3 mRNA [3, 4], regulating the switch from spermatogenesis to oogenesis in C. elegans
hermaphrodites. Molecular cloning revealed that Pumilio and FBF proteins share a
conserved RNA-binding domain with eight ~36 amino acid sequence repeats, which was
named a Pumilio Homology Domain or PUF domain [4–7]. The known target RNAs
suggested that both proteins recognize a sequence in the 3′ UTR containing a conserved
UGUR sequence (where R is a purine) [4, 6, 8–11]. Pumilio and FBF regulate stability or
translation of target mRNAs by recruiting effector protein complexes to their target RNAs.
The PUF proteins themselves seem to lack additional functional modules, and instead
protein-protein interactions, often with the RNA-binding domain, assemble different
complexes on the target RNAs [12–16]. The formation of complexes may also fine tune
RNA specificity [17]. PUF proteins utilize these activities to regulate stem cell maintenance,
cell proliferation and differentiation, and stress response (reviewed in [18, 19]).
RNA recognition code for native PUF proteins
The first crystal structures of PUF proteins revealed how the repeated sequences form a
series of α-helical repeats that assemble an arc of RNA-recognition helices (Fig. 1A) [20,
21]. A structure of human Pumilio1 in complex with an RNA ligand showed how each of
the eight RNA-recognition helices recognizes one base using amino acid side chains at
specific positions in the second of three α-helices in each PUF repeat (Fig. 1B) [22]. Two of
these side chains interact specifically with an edge of the base while a third side chain forms
a stacking interaction with the base. The second helix in each PUF repeat includes a 5-
residue sequence, designated here as 12xx5, where the side chain at the 2nd position stacks
with the recognized base and the side chains at the 1st and 5th positions contact the edge of
the RNA base [22, 23].
Mutagenesis confirmed that Nature had provided a remarkably simple code for base
recognition: glutamate and serine at the 1st and 5th positions recognize guanine; glutamine
and cysteine/serine recognize adenine; and glutamine and asparagine recognize uracil (Fig.
1C) [22, 24]. No code for cytosine was apparent from Nature, but one of the repeats (repeat
4) can accept any base. In vitro binding affinity is tight due to the many stacking interactions
between protein side chains and RNA bases. Wildtype human Pumilio1 binds to cognate
RNA with a Kd of 0.5 nM, while designed Pumilio1 mutants bind to their cognate RNAs
with Kds ranging from as tight as ~4 pM to 18 nM. The effect on binding of a single non-
cognate repeat is largest when a base other than G is presented opposite a G-specific repeat
(30–150-fold weaker) and smallest when a G is presented opposite an A-specific repeat
(1.5–3-fold weaker) [24]. Other non-cognate mismatches reduce binding 10–20 fold [24,
25], indicating the importance of most repeats for specificity. With this RNA recognition
code, in principle, the RNA-binding specificity of human Pumilio1 can be manipulated by
site-directed mutagenesis to recognize various RNA targets containing guanine, adenine and
uracil.
The identification of this recognition code and the ability to modify specificity of a PUF
repeat has facilitated the identification of the RNA recognition properties of other PUF
proteins. PUF proteins comprise a relatively small family of RNA-binding proteins with few
members in any organism. Humans and other mammals have two while Drosophila have
one. S. cerevisiae with six and C. elegans with nine are larger families. This is in contrast to
RNA recognition motif (RRM) proteins or KH (hnRNP K homology) domains, where
hundreds of proteins are found in an organism. Most PUF proteins are predicted to have
eight PUF repeats like human Pumilio1, and the base recognition side chains are highly
conserved. However, the RNA target sequences of these proteins are considerably more
diverse than would be expected from the strong conservation. The core target sequences
begin with a 5′ UGUR, but may contain from 8–10 bases with differing 3′ sequences.
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To reconcile this inconsistency, the Wickens lab at University of Wisconsin used the design-
ability of PUF repeat base recognition to determine the mode of recognition for additional C.
elegans PUF proteins [26, 27]. Beginning with FBF, the Wickens lab used the yeast three-
hybrid assay to measure RNA binding of cleverly designed PUF proteins. They had
determined that FBF with 8 PUF repeats bound to a core RNA sequence with 9 bases [28],
but was the ‘extra’ base positioned within the sequence or at the 3′ end? To answer this
question, they created designed FBF proteins where a specific repeat was mutated to
recognize a different base, and they determined the sequence specificity of the designed
proteins [27]. The change in sequence specificity vs. wildtype FBF established the register
of PUF repeats and RNA bases. They concluded that FBF targets possess an ‘extra’ base at
the 6th of 9 bases that is not recognized by the protein, and crystal structures have confirmed
it [29, 30].
Additional studies of the RNA target specificities of different PUF proteins have revealed
how Nature expands recognition properties using an assortment of variations on the theme
of the 1 PUF repeat:1 RNA base recognition observed for Pumilio 1 [26–28, 30–35]. Crystal
structures of PUF proteins with RNA ligands demonstrate that extra or other non-
specifically recognized bases within natural PUF target sequences may stack directly with
adjacent bases and/or be flipped away from the PUF protein recognition surface [23, 29, 30,
36, 37]. A specialized binding pocket in a subset of PUF proteins recognizes a cytosine base
upstream of the core sequence [30, 38], and forming a complex with a partner protein can
modify the recognition motif [17]. The combinations of such variations produce the unique
specificity of natural target recognition by PUF proteins.
The accumulated body of evidence from genome-wide RNA target identification, X-ray
crystal structures, in vitro RNA-binding assays, and systematic mutagenesis studies indicate
that PUF protein repeats toward the N- and C-termini recognize conserved RNA sequence
elements, while plasticity in RNA recognition is focused mainly at the central repeats 4 and
5. The conserved 5′ UGUR sequence in PUF protein target sequences is recognized by
repeats 5–8 (Fig. 1A). A downstream AU sequence is also conserved and recognized by
repeats 2 and 3 in many PUF proteins. Valley, et al. examined systematically the effect of
alanine mutation of either edge-interacting or base-stacking side chains on RNA-binding by
C. elegans FBF and yeast Puf3p and Puf4p [34]. They found that repeats 4 and 5 can often
tolerate alanine substitutions and proposed a “two-handed model” to describe PUF-RNA
interactions, where the N- and C-terminal PUF repeats “grasp” the conserved 3′ and 5′
sequences of RNA binding sites, respectively. Protein-specific variations in RNA
recognition are accommodated between them.
In the case of yeast Puf4p, plasticity in recognition allows binding to target RNAs with two
different recognition patterns. In many target sites, the 7th of 9 bases is flipped away from
the RNA-binding surface (7-flipped), driven by recognition of an adenosine at position 6 by
repeat 3 (5′-UGUAUA-n7-UA, where n7 is any base at position 7). In a second set of target
sites, the recognition pattern produces flipping of the 6th base (6-flipped) with an adenosine
at position 7 recognized by repeat 3 (5′-UGUAU-n6-AUA). The sequence of these 6-flipped
sites also matches the target sites of another yeast PUF protein, Mpt5p. Thus, Puf4p and
Mpt5p may dually regulate target mRNAs with six-flipped sites, while seven-flipped sites
are not recognized by Mpt5p and regulated only by Puf4p.
Stacking interactions in PUF-RNA recognition contribute substantially to the binding
energy, but the role of these interactions in binding specificity of PUF proteins is less well
understood. RNA sequence specificity can be changed by site-directed mutagenesis of only
the two edge-interacting side chains [24]. However, it appears that the identity of the third
amino acid side chain that stacks with the bases has been optimized for the natural
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specificities of PUF proteins [39]. Substitution of the stacking side chains in C. elegans FBF
broadens the range of RNA bases that can be tolerated at a particular position. The simple
approach of designing PUF specificity by altering edge-interacting side chains is typically
successful, but a better understanding of how stacking side chains contribute to specificity
may enhance target selectivity of designed proteins.
Expanding the modular binding code for cytosine
With the natural modularity and recognition code of human Pumilio 1, its PUF domain can
be engineered to target an eight-nucleotide RNA sequence containing adenine, uracil and
guanine [22, 24]. By fusing the PUF domain with a functional domain, these ‘designer’
PUFs have been applied to track RNA localization in cells [40, 41], regulate alternative
splicing [25, 42], and modulate translational regulation [43]. Opportunities remain to
develop novel tools for biomedical research with potential therapeutic applications (see
below).
A limitation to the application of designer PUFs had been that no recognition code for
cytosine specificity was found in Nature. However, two groups recently succeeded in
identifying combinations of amino acid side chains that specify cytosine recognition by a
PUF repeat, expanding the PUF recognition code and permitting the creation of PUFs
directed to any 8-base RNA sequence [25, 44]. Both groups used yeast three-hybrid
screening of a PUF domain library with random sequences at the 1st and 5th positions of the
RNA interaction motif in repeat 6 to select proteins that bound a cytosine at the
corresponding 3rd base of the RNA target. Dong, et al. found that a combination of serine at
the 1st position and arginine at the 5th position specify cytosine [25]. A crystal structure
showed hydrogen bonding between the side chain of arginine and the O2 and N3 positions
of the cytosine. The serine residue positions the arginine, but does not contact the RNA.
Using a similar strategy, Filipovska, et al. selected five PUF variants that specify cytosine
binding [44]. Each variant pairs an arginine at the 5th position with a small side chain at the
1st position. The ‘C code’ could be transferred to different PUF repeats, and tyrosine,
histidine, or arginine side chains at the 2nd position of the RNA interaction sequence are
capable of forming stacking interactions for cytosine recognition [25]. The identification of
the C code makes it now possible to design PUF domains that bind any 8-base RNA target
sequence and increases the potential for use of engineered PUF proteins in research and
therapeutics.
Engineered factors with PUF as RNA-binding scaffold
The unique RNA-binding mode of the PUF domain makes it possible to engineer artificial
proteins to modulate RNA metabolism. Following the composition of natural proteins, these
artificial proteins employ a modular design by fusing a functional module (protein domains
with desired activities) to a target recognition module (modified PUF domains with re-
designed RNA binding specificity). Compared with other domains that specifically bind
single-stranded RNA, such as RRM, Zn finger and pentatricopeptide repeats (PPR), the PUF
domain has the advantage of having a fully determined modular binding code. The RRM
and Zn finger domains only recognize short RNA motifs (3-4 nt), and their binding
specificity cannot be reprogrammed. However, it is conceivable that several RRMs or Zn
fingers can be tandemly linked to recognize a longer RNA. Similar to the PUF domain, the
PPR domain can recognize RNA in a modular fashion and several researchers have begun to
make progress in solving its modular binding code [45]. Once the binding code is
completed, the PPR may be used similarly to PUF as a modular RNA binding scaffold in
engineered factors. The main disadvantage of PUF is that the native protein contains only
eight repeats that recognize 8-nt target, however it is possible to expand the length of PUF
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recognition sites (described below). Varying the choice of functional modules, an assortment
of PUF factors has been engineered since 2007 and more factors with novel activities are
expected to be generated in the future.
Engineered PUF proteins as specific RNA probes
The first application of artificial PUF proteins was as a fluorescent marker to visualize
RNAs in live cells [40]. A highly effective approach to visualize RNAs in live cells is to use
a fusion protein of green fluorescent protein (GFP) fused to bacteriophage coat protein MS2
that recognizes reporter RNAs containing multiple copies (e.g. 24 copies) of MS2 hairpin
sequences [46, 47](reviewed in [48]). However, the GFP-MS2 fusion protein requires
artificial RNA targets with MS2 hairpins. To visualize endogenous RNA targets, Ozawa, et
al. designed a split GFP system that comprises two fusion proteins, each containing a PUF
domain and either an N-terminal or C-terminal fragment of GFP (Fig. 2A). When the PUF
domains recognize the adjacent 8-nt sequences in the same RNA, the two fusion proteins are
brought together so that the split GFP fragments assemble and fluoresce. The specificity of
this system is increased by requiring binding to two 8-nt sites separated by a small spacer.
This design has been used to visualize mitochondrial RNA in cultured mammalian cells
[40], cytosolic β-actin mRNA [49], and a modified version using intact GFP fused with two
PUFs was also used to detect cytosolic β-actin mRNA [50]. A similar approach was also
developed by Tilsner, et al, who combined PUF domains with split mCitrine and used it to
reveal plant viral RNA localization [41]. Another variation of this method used PUF
domains fused with split luciferase to detect ssRNA in vitro [51], however this approach has
not yet been tested in live cells.
The use of split fluorescent protein reduces the noise level of RNA detection, because the
fluorescent protein is assembled by the RNA target. However, because of the limited
efficiency in the co-folding of two GFP fragments and only one GFP per RNA, this system
produces lower fluorescent signal compared to the GFP-MS2. On the other hand, the PUF-
split GFP can detect a single endogenous RNA target, whereas the GFP-MS2 requires a
reporter RNA with multiple MS2 target sites to produce a higher signal over the diffuse
background noise of unbound fluorescent protein. For some special cases, it should be
possible to use the GFP-PUF fusion protein directly. Like the GFP-MS2 fusion protein, the
GFP-PUF will produce a weak fluorescence background. However, if the target contains
multiple copies of the recognition site, the GFP-PUF may form bright foci on the target
RNA, like the GFP-MS2 protein forms a bright spot on reporter RNAs with consecutive
MS2 hairpins [47]. Several trinucleotide expansions have been found to cause
neurodegenerative diseases (such as CAG repeats in Huntington disease and CUG repeats in
myotonic dystrophy, reviewed in [52]). These pathogenic RNA repeats usually contain
hundreds of copies of the trinucleotide, thus a GFP-PUF recognizing these repeated
sequences may provide a new way to visualize the RNA and study the dynamics of such
pathogenic RNA in live cells.
Engineered PUF proteins as regulatory factors for gene expression
Mammalian gene expression is controlled by multiple regulatory steps during mRNA
processing by protein factors with modular configuration: separable RNA recognition and
functional domains. A common method to study the function of RNA regulatory proteins is
to tether the protein or a fragment to a specific RNA target and analyze the consequences.
Using this engineering principle, artificial regulatory factors can be derived by combining a
PUF domain with different effector domains. For example, Wang, et al. developed
engineered splicing factors (ESFs) by fusing a PUF domain with Arg/Ser-rich (RS) domains
of SRSF1 or the glycine-rich (Gly) domain of hnRNP A1 (Fig. 2B) [42]. The resulting ESFs
can function either as splicing activators (PUF-RS) or inhibitors (PUF-Gly), and can
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specifically control different types of alternative splicing. Specifically, PUF-RS promotes
exon inclusion when binding to an alternative exon, but inhibits splicing when binding
downstream of an alternative exon. PUF-Gly, on the other hand, inhibits exon inclusion
when binding to the target RNA either inside or downstream of the alternative exon [42, 53].
When binding to the region between two alternative 5′ or 3′ splice sites, PUF-RS promotes
use of the proximal splice site to favor the longer splicing isoform, whereas PUF-Gly
inhibits proximal site usage to induce the shorter isoform [42].
Using this general approach, a PUF-Gly ESF was generated to shift splicing of the Bcl-x
pre-mRNA from the anti-apoptotic long isoform (Bcl-xL) to the pro-apoptotic short isoform
(Bcl-xS). The altered splice isoform distribution was sufficient to sensitize several cancer
cell lines to multiple anti-cancer drugs [42]. With the identification of the C code, both PUF-
RS and PUF-Gly ESFs were engineered to shift splicing of VEGF-A pre-mRNA from the
angiogenic to anti-angiogenic isoform [25].
Another elegant use of the modular configuration for RNA regulation was developed by
Cooke, et al. to alter translation [43]. They attached a PUF domain to either a translational
activator, GLD2, or a translational repressor, CAF1 (Fig. 2C). The resulting PUF-GLD2
engineered proteins specifically recognized their RNA target and activated translation and
induced polyadenylation in Xenopus oocytes, whereas the PUF-CAF1 fusion protein
repressed translation and directed deadenylation. The coordinate regulation of translation
and/or stability of mRNA by PUF proteins and miRNAs [54–57] suggests that engineered
PUF proteins may be designed to use as antagonizers or enhancers of miRNA regulation.
Engineered PUF proteins as novel RNA endonucleases
Specific cleavage of RNAs is critical for in vitro manipulation of RNA and for in vivo gene
silencing. However, a simple enzyme that cleaves RNA in a sequence-specific manner has
not been found in Nature despite extensive investigations. Most RNA endonucleases either
have limited sequence specificity (e.g., RNase A or RNase T1 [58–60]) or recognize their
targets by specific structures (e.g., tRNA splicing endonuclease [61]) or through guide RNA
that pairs with target (e.g., Argonaute proteins [62]). By fusing a PUF domain with a non-
specific endoribonuclease domain (PIN domain of Smg6p), Choudhury, et al. engineered
artificial site-specific RNA endonucleases (ASREs) that specifically recognize RNA
substrates and efficiently cleave near the binding sites both in vitro and in cultured cells
(Fig. 2D) [63]. The digested products have 5′-phosphate and 3′-hydroxyl groups, making it
possible to religate. Two ASREs were designed to silence specifically the expression of a
bacterial gene or human mitochondrial mRNAs that contain one or two binding sites of
designer PUFs. Since PUF domains recognize their targets through an 8-nt sequence,
comparable length to the seed match of siRNA, engineered ASREs may serve as an RNA
silencing tool complementary to RNAi, which will be effective in organisms or cellular
compartments where RNAi machinery is not present.
Future applications of PUF-based designer factors
Mammalian gene expression contains multiple RNA processing stages including RNA
splicing, polyadenylation, editing, translocation, translation and degradation, which are
under tight control by a variety of RNA-binding proteins. The reprogrammable RNA-
binding scaffold of the PUF domain makes it possible, and tempting, to create artificial
factors that can specifically modulate target RNAs at each processing stage. A benefit of
manipulating gene expression at the RNA level rather than the DNA level is that the effect is
often non-permanent and reversible. The factors can be engineered by fusing designer PUF
domains with a protein factor (or its functional domain) with known regulatory activity on
RNA metabolism. In theory, any protein that has demonstrated activity in a tethering
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experiment can be fused with PUF domains to produce novel artificial factors that target
endogenous RNA targets. Minimal functional domains can be determined by fusing
fragments of known regulatory factors to PUF domains and testing activity. Alternatively,
new functional modules can be identified by constructing a cDNA library of PUF domain
fusions and screening for RNA regulation. A previous review has proposed several ideas for
potential applications of engineered RNA-binding proteins [64], some of which have been
achieved successfully using the PUF scaffold (Fig. 2). Here we propose other potential
applications using the engineered PUF factors in humans, and similar applications can be
adapted to other organisms.
Engineering RNA editing enzymes
RNA editing is commonly found in many eukaryotes to generate specific sequence
substitutions and changes in gene expression levels, resulting in increase of RNA and
protein diversity. Adenosine-to-inosine (A-to-I) editing represents the most important class
of RNA editing in human and affects function of many genes, especially in the central
nervous system (recently reviewed in [65]). The native substrate for A-to-I editing is a
double-stranded RNA (dsRNA) region, recognized by the adenosine deaminase acting on
RNA (ADAR). Canonical ADAR proteins have a conserved catalytic deaminase domain and
one or more dsRNA-binding domains (dsRBDs), however there is no report on whether
these domains function in a modular fashion [65]. Thus we propose replacing the dsRBDs
with a PUF domain and testing whether the resulting fusion factors have deaminase
activities against single-stranded RNA (Fig. 3A). With optimization, the engineered enzyme
may specifically recognize an RNA target by sequence and deaminate a nearby adenosine.
Next generation engineered splicing factors
Most human genes undergo alternative splicing to produce multiple isoforms with distinct
activities. This process is tightly regulated, and the mis-regulation of splicing is a common
cause of human diseases [66]. The specific manipulation of alternative splicing will provide
a useful way to fine tune gene function. Many known splicing factors have modular
activities in which they recognize a short RNA element in the target with an RNA-binding
module (e.g., RRM or KH domain) and alter splicing with a functional module. The best-
known functional domains for splicing modulation are the RS domains and Gly-rich
domains, which were used to develop the first generation of engineered splicing factors [25,
42]. However, other domains in splicing regulatory factors may have distinct activities in
regulating splicing. For example, we found that the C-terminal domain of several SR
proteins can activate or inhibit splicing when binding to different pre-mRNA regions [67],
the alanine-rich motif of RBM4 can inhibit splicing, and the proline-rich motif of DAZAP1
can enhance splicing [68]. These new functional domains can be used to derive additional
types of artificial splicing factors to fine tune alterative splicing (Fig. 3B).
Engineered factors to control alternative polyadenylation
Many human genes contain multiple polyadenylation sites. The use of different
polyadenylation sites creates mRNA isoforms with different 3′ UTRs that regulate the
translation efficiency and stability of mRNA. Like alternative splicing, control of alternative
polyadenylation can have multifaceted effects on biological processes, and shortening of the
3′ UTR through proximal polyadenylation site usage is closely regulated in cell proliferation
and differentiation [69–71]. Thus reprogramming the 3′ UTR region by modulating
polyadenylation site selection may provide another way to manipulate gene expression.
Several recent reports suggested that alternative polyadenylation is regulated by trans-acting
factors that recognize cis-elements near polyadenylation sites [72–74]. Some of these factors
can control both splicing and poly-adenylation (eg. U1A, PTB) [72, 74]. Therefore we
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expect engineered PUF fusion proteins to be similarly successful in modulating the use of
alternative polyadenylation sites (Fig. 3C).
Engineered factors to control RNA localization
The transport of RNA to correct intracellular locations is an essential step for the expression
of both coding and non-coding messages, as the function of RNA is highly localized. While
there are many known RNA elements that govern their transport and final localization, other
recognition elements are unknown and the detailed mechanisms are unclear. On the other
hand, protein localization signals are better understood and well characterized signal
peptides or fragments have been established that are responsible for protein localization in
nuclear or cytoplasmic compartments or for protein secretion. Therefore, by combining
these established protein localization signals with PUF domains, we may create engineered
factors to specifically transport RNA (Fig. 3D). For example, a PUF domain fused with a
nuclear localization sequence (NLS) may be created to block nuclear-to-cytoplasmic RNA
transport. Such engineered proteins can be designed to recognize the loop-region of a
specific pre-miRNA, thus retaining the pre-miRNA in the nucleus and preventing its
processing to mature form in the cytoplasm, thereby inhibiting the miRNA function.
Engineered PUF factors to affect RNA stability
Turnover of mRNA is continuous in the cytoplasm and often regulated by protein factors
that recognize the 3′ UTR region. A well-studied case is directed by AU-rich elements in the
3′ UTR of short-lived mRNA, which destabilize the messages (reviewed in [75]). Several
factors positively or negatively regulate this process, and PUF fusion proteins with
fragments of these factors may function as engineered factors to modulate RNA stability
(Fig. 3E).
Engineered PUF transcriptional regulators
RNA transcription can be controlled at the initiation-to-elongation switch of RNA
polymerase II through a transcriptional pausing step after the initiation and synthesis of a
small RNA fragment (reviewed recently in [76]). Such pausing is released to continue
transcription, which is often controlled by transcription elongation factors. Using PUF
engineered factors that recognize the nascent transcripts, it may be possible to design factors
that specifically control transcription at the initiation-to-elongation switch by promoting or
releasing the paused RNA polymerase II (Fig. 3F). For example, the release of paused RNA
polymerase II can be mediated by CDK9 and Cyclin T1, which form a tightly complex to
promote transcription elongation [77]. It may be possible to recruit CDK9 through a PUF-
CDK9 fusion protein to the nascent transcripts, which in turn releases paused polymerase II
and activates transcription elongation.
Additional challenges for engineered PUF factors
Expanding binding specificity
Most naturally occurring PUF proteins have eight RNA-binding repeats, which recognize 8
bases in target mRNA. Some PUF domains can accommodate one or two extra bases,
however, the specificity of the extra bases cannot be reprogrammed. Thus the sequence
specificity of engineered PUF factors is largely determined by an 8-nt PUF binding site,
which is comparable to the specificity of miRNA that recognize targets by 7-nt seed match.
However, like miRNA, designer PUF factors may have off-target effects, since on average
any given 8-nt sequence will occur by chance in sequences with 48 bases or 64 kb in length.
Nevertheless it is possible to increase the specificity of engineered PUF factors. One
obvious approach is to use two PUF domains in combination, which in theory provides a
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recognition site of 16 nts. This design was used first for the visualization of RNA in vivo
with two fusion proteins of PUF domains and split GFP fragments [40] and later was used
by creating a fusion protein containing two PUF domains separated by an intact GFP protein
[50]. Specificity for a 16-nt sequence should ensure the recognition of a unique target in the
human transcriptome. However, engineered factors with tandem PUF domains may
recognize an 8-nt ‘half-site’ with sufficient affinity for functional activity. An alternative
approach is to construct an expanded PUF domain by inserting more PUF repeats into a
native PUF domain. For example, a PUF domain with 16 repeats was demonstrated to bind
cognate RNA target in a yeast-three-hybrid assay [44], and it should be possible to construct
PUF domains with different numbers of repeats using similar design. We have generated
expanded PUF domains with nine, ten or twelve PUF repeats and found that these novel
PUF scaffolds can indeed recognize cognate targets (Zhang and Wang, unpublished results).
While most applications will benefit from a PUF domain with increased specificity, in
certain cases the engineered PUF factors may need to recognize multiple diverse targets with
a degenerate binding code (i.e. a decreased specificity). This requires generating PUF
domains that recognize shorter target sequences. Two strategies may solve this problem.
One is to identify amino acid side chain combinations in PUF repeats that can tolerate
multiple or all bases to produce a binding code for “N”. This degenerate code can be used in
combination with the specific base recognition code to make new PUF domains that
specifically recognize sequences shorter than 8-nt while maintaining binding affinity. We
suggest it may be possible to screen for a degenerate code of PUF-RNA interaction. Another
approach is to construct a PUF scaffold with fewer than 8 PUF repeats. The minimum
number of repeats in a stable PUF scaffold is unknown, but we speculate that a minimal
number may be required for correct folding. Using a PUF scaffold with fewer repeats also
decreases the size of the engineered protein, which may be beneficial for in vivo
applications and simplify the design.
Minimizing off-target effects
The control of off-target effects is an important concern for any method that specifically
targets endogenous gene expression, especially when the engineered PUF factors are used in
vivo. In addition to using a PUF scaffold with higher specificity (e.g., a scaffold containing
additional repeats), careful experimental design should minimize off-target effects.
The first opportunity to minimize off-target effects is in the design stage by identifying a
target sequence with fewer off-target hits in unrelated RNAs. Since the sequence of the
human genome is not random, some sequence patterns are more common than others. When
selecting PUF recognition sites in RNA targets, it will be helpful to search the transcriptome
and choose relatively uncommon sites. While off-target effects are impossible to eliminate,
such a search will estimate the frequency of possible off-target sites. Another concern in
selecting target sequences is evaluating how RNA structure may affect PUF binding. While
the PUF scaffold can recognize an RNA target sequence in a double-stranded region [44, 54]
(Wang, unpublished result), the occurrence of extensive hairpin structures in the binding site
greatly decreases binding affinity (Wang, unpublished result). Therefore, we should select
target sites in less structured regions, whereas possible off-target sites in more structured
regions may not pose a problem.
Another method to reduce off-target effects is to control the expression of the engineered
PUF factors by expressing them at the same time and place as their targets. For example, by
designing an ASRE with mitochondrial targeting signals to silence mitochondrial RNA, we
produced a protein with low off-target effects against nuclear or cytoplasmic RNA, as the
ASRE is undetectable outside mitochondria [63]. A wide array of gene expression tools
have been developed over the years to fine tune expression of exogenous proteins (such as
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cell type specific vectors). They should be helpful tools to fine tune the expression pattern of
the engineered PUF factors.
In vivo delivery of engineered PUF factors
Since engineered PUF factors are typical proteins, they should be deliverable to live animals
using established gene therapy vectors. For application in cultured cells or animal models,
the lentiviral system is a good choice for ease of use and robust expression in most cell
types. For therapeutic applications in humans, adeno-associated virus (AAV) is a favorable
choice in gene therapy, because it lacks known pathogenicity, can infect non-dividing cells,
and has many serotypes that allow specific gene delivery into different tissues. The AAV
can stably integrate into the host cell genome at a specific site (designated AAVS1) in
human chromosome 19 [78, 79], however the non-integrating AAV vectors are used for all
gene therapy applications. The drawback of AAV is its small package capacity, but the
current engineered PUF factors are small enough to be packed by AAV.
Several non-viral methods may be used to deliver DNAs or proteins into animals, and some
of these methods are under testing for use in humans. These methods include different nano-
particles and cell penetration peptides, and more in depth information on in vivo delivery
methods can be found in related reviews [80–82]. These methods can be applied, at least in
principle, for in vivo delivery of the engineered PUF factors. Since the application of
engineered PUF factors is still in early stages, we expect the technology for protein delivery
to advance ahead of the in vivo application of these factors in live animals or humans.
Final comments
Thus far engineered factors combining a PUF scaffold with a functional module have proven
to be versatile tools for manipulating and understanding RNA metabolism. Recent advances
allowing design of the PUF scaffold to recognize any RNA sequence expand the potential to
apply this technology to regulate RNA regulatory processes. Starting with the gift of
Nature’s design, continued adherence to the rule of simplicity may be prudent in moving this
new field forward.
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PUF domain RNA interaction scaffold. A. Ribbon diagram of a crystal structure of human
Pumilio 1 RNA-binding domain in complex with RNA ligand (5′-UGUACAUA). RNA
interaction helices are shown as light blue cylinders and labeled R1–R8. Edge-interacting
side chains from each repeat are colored light blue, stacking side chains are colored pink,
and RNA is colored peach. For stick representations, nitrogen atoms are blue, oxygen atoms
are red, and sulfur atoms are yellow. B. Interaction of PUF repeats with uracil or adenine
bases. Hydrogen bonds or van der Waals contacts are indicated by dotted lines. C. PUF
RNA interaction code. Edge-interacting side chains that specify base recognition are shown.
G, A, and U were derived from natural PUF proteins while C recognition was selected by
screening.
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Engineered PUF factors. A. Fluorescent probe for in vivo RNA labeling. Combination of
split GFP (or other fluorescent protein) with PUF scaffold generated an RNA probe to
visualize RNA in live cells. B. Engineered splicing factors. Combination of a PUF scaffold
with an RS domain or a Gly-rich domain generated splicing factors that activate or inhibit
splicing of alternative exon. C. Modulation of translation. Fusion of GLD2 or CAF1 with
PUF domain produced novel factors that can activate or inhibit mRNA translation. D.
Artificial site-specific RNA endonuclease. Combination of PUF domain with a non-specific
RNA endonuclease (PIN domain) can produce a new class of enzymes that specifically
recognize and cleave RNA.
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Future engineered factors with PUF scaffold as RNA recognition module. A. Novel enzyme
for single-stranded RNA editing. Sequence specificity may be determined by a PUF binding
site rather than double-stranded RNA. B. Next generation engineered splicing factors. With
recently identified functional domains that control splicing in diverse fashion, new splicing
factors may be generated to fine tune alternative splicing. C. Engineered PUF factors to
manipulate alternative polyadenylation. By combining a PUF domain with regulatory
proteins/domains for alternative polyadenylation sites, artificial factors may be constructed
to inhibit or activate certain polyadenylation sites and thus change the 3′ UTR of mRNA. D.
Engineered RNA transporters. New proteins can be engineered by combining a PUF domain
with protein translocation signals to transport RNA into different cellular compartments. E.
Wang et al. Page 18













Engineered PUF factors to control RNA degradation. The PUF domain can be linked with
additional domains to specifically recruit RNA stabilization or destabilization proteins, thus
controlling RNA half-life. F. Engineered PUF factors to control transcription elongation. By
specifically recognizing the nascent RNA transcript, new PUF factors can be engineered to
induce transcription pausing or release paused RNA polymerases.
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